Tag: Cirrhosis
-

Resolution Therapeutics Announces Regenerative Macrophage Therapy Data for Cirrhosis at AASLD 2025
Overview: New Data Spotlight Regenerative Macrophage Therapy Resolution Therapeutics has announced key updates from its ongoing research into Regenerative Macrophage Therapy (RMT) for cirrhosis, with fresh data presented at AASLD 2025. The company highlighted early signals from the MATCH Phase II study showing that patients receiving non-engineered macrophages exhibit early improvements in liver function. In…
-

Resolution Therapeutics unveils regenerative macrophage therapy data for cirrhosis at AASLD 2025
Resolution Therapeutics presents hopeful data on regenerative macrophage therapy for cirrhosis at AASLD 2025 Resolution Therapeutics has announced new data from its portfolio of macrophage-based therapies at the AASLD 2025 conference. The company highlighted early clinical signals from the MATCH Phase II study, which evaluate the potential of non-engineered macrophages to repair cirrhotic livers and…
-

Resolution Therapeutics Unveils Early MATCH Phase II Data; Regenerative Macrophage Therapy Shows Promise for Cirrhosis at AASLD 2025
Groundbreaking DATA at AASLD 2025 Resolution Therapeutics presented new clinical and preclinical data at AASLD 2025 highlighting the potential of Regenerative Macrophage Therapy for cirrhosis. The company reported early improvements in liver function in the MATCH Phase II study using non-engineered macrophages, with associations to favorable long-term clinical outcomes. These findings position Resolution’s macrophage-based approach…
-

CORE Model: Simple Blood Tests Predict Liver Disease Risk
What is the CORE model? A new tool, the CORE model, is being developed to help primary care teams assess the risk of serious liver diseases. The aim is to identify patients who are at higher risk of conditions such as cirrhosis, liver cancer, or the potential need for a liver transplant within the next…
-

Simple Test Predicts Liver Disease: CORE Model Uses Three Blood Tests
What is the CORE model? A new risk-prediction tool called CORE has been developed to help primary care. It uses information from three simple blood tests that are already collected in routine checkups to estimate a patient’s ten-year risk of developing serious liver problems, including cirrhosis, liver cancer, or the need for a liver transplant.…
-

CORE Model Uses Three Blood Tests to Predict Liver Disease Risk
What is the CORE model and why it matters Liver disease is on the rise, and outcomes worsen when it is detected late. A new tool, known as the CORE model, has been developed to help primary care clinicians assess a patient’s risk of severe liver conditions before symptoms appear. By relying on three simple…
-

New Blood Test Reveals Future Risk of Severe Liver Disease
Researchers at Karolinska Institutet in Sweden have developed a simple blood test that can predict the risk of developing a severe liver disease within ten years. The test, designed for use in primary care, could help catch cirrhosis and liver cancer long before symptoms appear. What is the new liver disease risk test? The method…
-

New liver disease risk test could predict severe disease in a decade
Overview A new blood-based method developed at Karolinska Institutet offers a way to predict the risk of developing severe liver disease within ten years. The simple blood analysis is designed for use in primary care to identify individuals who are at higher risk of progressing to conditions such as cirrhosis or liver cancer. If validated…
-

New Blood Test Could Predict Severe Liver Disease in 10 Years
Overview Researchers at Karolinska Institutet have developed a simple blood analysis that may predict the risk of developing a serious liver disease within ten years. The test is designed for use in primary care, with the goal of spotting people at high risk for cirrhosis and liver cancer before symptoms appear. In initial studies, the…

